Repositioning Candidate Details
| Candidate ID: | R0114 |
| Source ID: | DB00408 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Loxapine |
| Synonyms: | |
| Molecular Formula: | C18H18ClN3O |
| SMILES: | CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2 |
| Structure: |
|
| DrugBank Description: | An antipsychotic agent used in schizophrenia. [PubChem] |
| CAS Number: | 1977-10-2 |
| Molecular Weight: | 327.808 |
| DrugBank Indication: | For the management of the manifestations of psychotic disorders such as schizophrenia |
| DrugBank Pharmacology: | Loxapine, a dibenzoxazepine compound, represents a subclass of tricyclic antipsychotic agents, chemically distinct from the thioxanthenes, butyrophenones, and phenothiazines. Pharmacologically, Loxapine is a tranquilizer for which the exact mode of action has not been established, however, it is believed that by antagonising dopamine and serotonin receptors, there is a marked cortical inhibition which can manifest as tranquilization and suppression of aggression. |
| DrugBank MoA: | Loxapine is a dopamine antagonist, and also a serotonin 5-HT2 blocker. The exact mode of action of Loxapine has not been established, however changes in the level of excitability of subcortical inhibitory areas have been observed in several animal species in association with such manifestations of tranquilization as calming effects and suppression of aggressive behavior. |
| Targets: | 5-hydroxytryptamine receptor 2A; Dopamine D2 receptor; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 1B; 5-hydroxytryptamine receptor 1D; 5-hydroxytryptamine receptor 1E; 5-hydroxytryptamine receptor 3A; 5-hydroxytryptamine receptor 5A; 5-hydroxytryptamine receptor 6; 5-hydroxytryptamine receptor 7; Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; Alpha-2A adrenergic receptor; Alpha-2B adrenergic receptor; Alpha-2C adrenergic receptor; Beta-1 adrenergic receptor; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M4; Muscarinic acetylcholine receptor M5; D(1) dopamine receptor; Dopamine D3 receptor; Dopamine D4 receptor; Dopamine D5 receptor; Histamine H1 receptor; Histamine H2 receptor; Histamine H4 receptor; Sodium-dependent serotonin transporter; Sodium-dependent noradrenaline transporter; Sodium-dependent dopamine transporter; Dopamine D1 receptor |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I02 | 1184 | nephrotic syndrome | "A nephrosis characterized by marked increase in glomerular protein permeability resulting in marked elevation of urine protein levels, hypoalbuminemia, hyperlipidemia, and hypercoagulability." [url:https\://en.wikipedia.org/wiki/Nephrotic_syndrome, url:https\://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults] | Details |